share_log

科濟藥業-B：更換核數師

CARSGEN-B: CHANGE OF AUDITOR

香港交易所 ·  Jan 12 09:40
Summary by Moomoo AI
科济药业宣布，由于未能与羅兵咸永道会计师事务所就2023年年度业绩达成双方接受的审计时间表，羅兵咸永道已于2024年1月12日辞任公司核数师。羅兵咸永道辞任前提出，美国子公司收到FDA要求暂停部分临床试验，并指出公司存在若干问题，包括信用卡使用控制、员工逾期居留及文件规范偏差等。科济药业已对这些问题进行内部审查并采取措施。董事会随后决定委任安永会计师事务所为新核数师，任期至下届股东年会结束。公司对羅兵咸永道过往的服务表示感谢，并欢迎安永担任新核数师。
科济药业宣布，由于未能与羅兵咸永道会计师事务所就2023年年度业绩达成双方接受的审计时间表，羅兵咸永道已于2024年1月12日辞任公司核数师。羅兵咸永道辞任前提出，美国子公司收到FDA要求暂停部分临床试验，并指出公司存在若干问题，包括信用卡使用控制、员工逾期居留及文件规范偏差等。科济药业已对这些问题进行内部审查并采取措施。董事会随后决定委任安永会计师事务所为新核数师，任期至下届股东年会结束。公司对羅兵咸永道过往的服务表示感谢，并欢迎安永担任新核数师。
KOZAI PHARMACEUTICALS ANNOUNCED THAT DUE TO THE FAILURE OF THE PARTIES TO REACH AN AUDIT TIMETABLE FOR 2023 WITH THE ACCOUNTING FIRM OF ROBINGHAM SUNGAO, IT HAS RESIGNED AS AUDITOR OF THE COMPANY ON 12 JANUARY 2024. Prior to his tenure, the U.S. subsidiary received an FDA request to suspend some clinical trials, citing a number of problems with the company, including credit card usage controls, employee late stays, and document regulatory discrepancies, among others. Kozai Pharmaceuticals has conducted internal reviews and measures on these issues. The Board of Directors subsequently decided to appoint EY Accountants as the new Auditor for a term of office until the end of the next Annual General Meeting. The Company expresses its gratitude for its past service and welcomes the appointment of new auditors at EY.
KOZAI PHARMACEUTICALS ANNOUNCED THAT DUE TO THE FAILURE OF THE PARTIES TO REACH AN AUDIT TIMETABLE FOR 2023 WITH THE ACCOUNTING FIRM OF ROBINGHAM SUNGAO, IT HAS RESIGNED AS AUDITOR OF THE COMPANY ON 12 JANUARY 2024. Prior to his tenure, the U.S. subsidiary received an FDA request to suspend some clinical trials, citing a number of problems with the company, including credit card usage controls, employee late stays, and document regulatory discrepancies, among others. Kozai Pharmaceuticals has conducted internal reviews and measures on these issues. The Board of Directors subsequently decided to appoint EY Accountants as the new Auditor for a term of office until the end of the next Annual General Meeting. The Company expresses its gratitude for its past service and welcomes the appointment of new auditors at EY.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more